A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome

POS0193 EVALUATION OF CRESS IN THE PHASE 2 RANDOMISED PLACEBO-CONTROLLED STUDY OF SEQUENTIAL BELIMUMAB/RITUXIMAB ADMINISTRATION IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME

(2022) H. Bootsma et al.   ANNALS OF THE RHEUMATIC DISEASES

OP0129 BELIMUMAB AFTER RITUXIMAB SIGNIFICANTLY REDUCED IGG ANTI-DSDNA ANTIBODY LEVELS AND PROLONGED TIME TO SEVERE FLARE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

(2021) M. Shipa et al.   ANNALS OF THE RHEUMATIC DISEASES

OP0135 SAFETY AND EFFICACY OF SUBCUTANEOUS BELIMUMAB AND INTRAVENOUS RITUXIMAB COMBINATION IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME: A PHASE 2, RANDOMISED, PLACEBO-CONTROLLED 68-WEEK STUDY

(2021) X. Mariette et al.   ANNALS OF THE RHEUMATIC DISEASES

Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure

(2021) Suzanne Arends et al.   Lancet Rheumatology

Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

(2021) Simon J Bowman et al.   LANCET

Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren’s syndrome

(2020) Emmanuella Young Traianos et al.   RHEUMATOLOGY INTERNATIONAL

Efficacity of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sjögren syndrome refractory to rituximab alone

(2020) Kevin Chevalier et al.   ANNALS OF THE RHEUMATIC DISEASES

CALIBRATE: A Phase 2 Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis

(2020) Yemil Atisha‐Fregoso et al.   Arthritis & Rheumatology

Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis

(2020) Richard Furie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol

(2019) Y K Onno Teng et al.   BMJ Open

Pain and fatigue in primary Sjögren’s syndrome

(2019) Roald Omdal et al.   RHEUMATOLOGY

Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity

(2019) Thomas Dörner et al.   ANNALS OF THE RHEUMATIC DISEASES

Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: A French nationwide study

(2019) Guillaume Bayer et al.   European Journal of Internal Medicine

EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies

(2019) Manuel Ramos-Casals et al.   ANNALS OF THE RHEUMATIC DISEASES

The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus

(2018) Tineke Kraaij et al.   JOURNAL OF AUTOIMMUNITY

Primary Sjögren’s Syndrome

(2018) Xavier Mariette et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of primary Sjögren’s syndrome: recent developments and new classification criteria

(2018) Nicoletta Del Papa et al.   Therapeutic Advances in Musculoskeletal Disease

Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis

(2018) Liliana Michelle Gomez Mendez et al.   Clinical Journal of the American Society of Nephrology

Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren’s syndrome

(2018) Saba Nayar et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis

(2018) Tamara H Ramwadhdoebe et al.   RHEUMATOLOGY

Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome

(2017) Simon J. Bowman et al.   Arthritis & Rheumatology

Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus

(2016) Jennifer Witcher et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The BAFFling effects of rituximab in lupus: danger ahead?

(2016) Michael R. Ehrenstein et al.   Nature Reviews Rheumatology

Rituximab Effectiveness and Safety for Treating Primary Sjögren’s Syndrome (pSS): Systematic Review and Meta-Analysis

(2016) Francine Bertolais do Valle Souza et al.   PLoS One

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

(2015) D A Isenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis

(2015) J Wild et al.   LEUKEMIA

Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren’s syndrome

(2015) Elena Pontarini et al.   RHEUMATOLOGY

Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials

(2015) William Stohl et al.   ARTHRITIS RESEARCH & THERAPY

CXCL13 and CCL11 Serum Levels and Lymphoma and Disease Activity in Primary Sjögren's Syndrome

(2015) G. Nocturne et al.   Arthritis & Rheumatology

Treatment of Primary Sjögren Syndrome With Rituximab

(2014) Valérie Devauchelle-Pensec et al.   ANNALS OF INTERNAL MEDICINE

Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)

(2014) Raphaèle Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

Belimumab after rituximab as maintenance therapy in lupus nephritis

(2014) T. Kraaij et al.   RHEUMATOLOGY

A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate

(2013) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study

(2013) Xavier Mariette et al.   ANNALS OF THE RHEUMATIC DISEASES

Advances in understanding the pathogenesis of primary Sjögren's syndrome

(2013) Gaëtane Nocturne et al.   Nature Reviews Rheumatology

Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy

(2012) Nishath Hamza et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry

(2012) Jacques-Eric Gottenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

(2012) William Stohl et al.   ARTHRITIS AND RHEUMATISM

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus

(2012) DJ Wallace et al.   LUPUS

Topical and systemic medications for the treatment of primary Sjögren's syndrome

(2012) Manuel Ramos-Casals et al.   Nature Reviews Rheumatology

EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome

(2011) R. Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of rituximab in primary Sjögren's syndrome with peripheral nervous system involvement: results from the AIR registry

(2011) A Mekinian et al.   ANNALS OF THE RHEUMATIC DISEASES

Response to rituximab in patients with rheumatoid arthritis in different compartments of the immune system

(2011) Maria J. H. Boumans et al.   ARTHRITIS AND RHEUMATISM

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations

(2011) Y Mishima et al.   Blood Cancer Journal

Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomized, double-blind, placebo-controlled trial

(2010) J. M. Meijer et al.   ARTHRITIS AND RHEUMATISM

Targeting B cells in immune-mediated inflammatory disease: A comprehensive review of mechanisms of action and identification of biomarkers

(2010) Thomas Dörner et al.   PHARMACOLOGY & THERAPEUTICS

Rituximab: Mechanism of Action

(2010) George J. Weiner   SEMINARS IN HEMATOLOGY

Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome

(2009) J. Pijpe et al.   ARTHRITIS AND RHEUMATISM

Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study

(2008) S Dass et al.   ANNALS OF THE RHEUMATIC DISEASES

BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells

(2008) G. Badr et al.   BLOOD

Rituximab: Beyond Simple B Cell Depletion

(2008) A. Kessel et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY